157 related articles for article (PubMed ID: 25752388)
1. Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: evaluation of outcomes in the Regione Emilia-Romagna, Italy.
Showalter TN; Hegarty SE; Rabinowitz C; Maio V; Hyslop T; Dicker AP; Louis DZ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):752-9. PubMed ID: 25752388
[TBL] [Abstract][Full Text] [Related]
2. Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort.
Hegarty SE; Hyslop T; Dicker AP; Showalter TN
PLoS One; 2015; 10(2):e0118430. PubMed ID: 25706657
[TBL] [Abstract][Full Text] [Related]
3. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
4. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial.
Katayama S; Striecker T; Kessel K; Sterzing F; Habl G; Edler L; Debus J; Herfarth K
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):926-33. PubMed ID: 25216858
[TBL] [Abstract][Full Text] [Related]
6. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
[TBL] [Abstract][Full Text] [Related]
7. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up.
Buckstein M; Carpenter TJ; Stone NN; Stock RG
Urology; 2013 Feb; 81(2):364-8. PubMed ID: 23374803
[TBL] [Abstract][Full Text] [Related]
9. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
10. Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy.
Formenti SC; Lieskovsky G; Simoneau AR; Skinner D; Groshen S; Chen SC; Petrovich Z
J Urol; 1996 Feb; 155(2):616-9. PubMed ID: 8558674
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.
Miller DC; Sanda MG; Dunn RL; Montie JE; Pimentel H; Sandler HM; McLaughlin WP; Wei JT
J Clin Oncol; 2005 Apr; 23(12):2772-80. PubMed ID: 15837992
[TBL] [Abstract][Full Text] [Related]
12. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
[TBL] [Abstract][Full Text] [Related]
13. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.
Potosky AL; Legler J; Albertsen PC; Stanford JL; Gilliland FD; Hamilton AS; Eley JW; Stephenson RA; Harlan LC
J Natl Cancer Inst; 2000 Oct; 92(19):1582-92. PubMed ID: 11018094
[TBL] [Abstract][Full Text] [Related]
14. Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up.
Ferrer M; Guedea F; Suárez JF; de Paula B; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Boladeras A; Ayala A; Craven-Bratle J; Ávila M; Cunillera O; Pardo Y; Alonso J; Aguiló F;
Radiother Oncol; 2013 Aug; 108(2):306-13. PubMed ID: 23849168
[TBL] [Abstract][Full Text] [Related]
15. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study.
Penson DF; McLerran D; Feng Z; Li L; Albertsen PC; Gilliland FD; Hamilton A; Hoffman RM; Stephenson RA; Potosky AL; Stanford JL
J Urol; 2005 May; 173(5):1701-5. PubMed ID: 15821561
[TBL] [Abstract][Full Text] [Related]
16. Expanded Prostate Cancer Index Composite versus Incontinence Symptom Index and Sexual Health Inventory for Men to measure functional outcomes after prostatectomy.
Hedgepeth RC; Labo J; Zhang L; Wood DP
J Urol; 2009 Jul; 182(1):221-7; discussion 227-8. PubMed ID: 19450842
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
18. Long-term evaluation of survival, continence and potency (SCP) outcomes after robot-assisted radical prostatectomy (RARP).
Ficarra V; Borghesi M; Suardi N; De Naeyer G; Novara G; Schatteman P; De Groote R; Carpentier P; Mottrie A
BJU Int; 2013 Aug; 112(3):338-45. PubMed ID: 23470027
[TBL] [Abstract][Full Text] [Related]
19. Effect of minimally invasive radical prostatectomy in older men.
Adejoro O; Gupta P; Ziegelmann M; Weight C; Konety B
Urol Oncol; 2016 May; 34(5):234.e1-11. PubMed ID: 26795606
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
